MAP3K12 and Alzheimer disease: Increased DLK activity is also reported in animal models of neurodegeneration, and genetically or pharmacologically inhibiting DLK in the aged PS2APP mice for AD and the SOD1G93A mice for ALS has resulted in some neuroprotective effects (Le Pichon et al., 2017).